Dr. Chengcheng “Alec” Zhang, Morton H. Sanger Professorship in Oncology and Michael L. Rosenberg Scholar for Biomedical Research at UT Southwestern, earned his B.S. from University of Science and Technology of China and Ph.D. from University of Illinois at Urbana-Champaign. After postdoctoral training at Harvey Lodish’s lab of Whitehead Institute, he established his lab at UT Southwestern in 2007. He is studying the signaling and function of immune surface molecules (including leukocyte immunoglobulin-like receptor family B, or LILRBs) in hematopoietic cells and developing novel therapies for treatment of hematologic malignancies and other cancers. He published >109 peer-reviewed articles, and was a recipient of several awards, including American Society of Hematology Junior Faculty Scholar Award and Leukemia & Lymphoma Society Scholar Award. Two anti-LILRB blocking antibodies developed by the team are in phase 1 clinical trials for treatment of myeloid leukemia and solid cancers.